scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCPH
CUSIPN/A
Phone617-517-0730
Debt
Debt-to-Equity Ratio0.10
Current Ratio19.23
Quick Ratio19.23
Price-To-Earnings
Trailing P/E Ratio-0.73
Forward P/E Ratio-2.19
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.02 per share
Price / Book0.98
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees29
Outstanding Shares18,540,000
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) posted its quarterly earnings data on Monday, May, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. View Scpharmaceuticals' Earnings History.
What price target have analysts set for SCPH?
3 Wall Street analysts have issued twelve-month price targets for Scpharmaceuticals' shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate Scpharmaceuticals' stock price to reach $12.6667 in the next twelve months. View Analyst Ratings for Scpharmaceuticals.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include Clementia Pharmaceuticals (CMTA), Synergy Pharmaceuticals (SGYP), GTX (GTXI), Syros Pharmaceuticals (SYRS), Bellicum Pharmaceuticals (BLCM), Dermira (DERM), Achillion Pharmaceuticals (ACHN), Axovant Sciences (AXON), American Brivision (Holding) (ABVC), Savara (SVRA), Albireo Pharma (ALBO), Tyme Technologies (TYME), Unum Therapeutics (UMRX), Corvus Pharmaceuticals (CRVS) and Verastem (VSTM).
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO & Director (Age 55)
- Dr. Troy A. Ignelzi, Chief Financial Officer (Age 50)
- Mr. Abraham Ceesay, Chief Operating Officer (Age 40)
- Dr. Klaus R. Veitinger M.D., Director (Age 56)
- Dr. Pieter Muntendam M.D., Consultant (Age 60)
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
When did the company's lock-up period expire?
Scpharmaceuticals' lock-up period expired on Wednesday, May 16th. Scpharmaceuticals had issued 6,400,000 shares in its public offering on November 17th. The total size of the offering was $89,600,000 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
Has Scpharmaceuticals been receiving favorable news coverage?
News headlines about SCPH stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Scpharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also gave media headlines about the company an impact score of 46.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Scpharmaceuticals' major shareholders?
Scpharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.56%), DAFNA Capital Management LLC (0.30%), Northern Trust Corp (0.26%), Citigroup Inc. (0.21%), Schwab Charles Investment Management Inc. (0.07%) and California State Teachers Retirement System (0.06%). View Institutional Ownership Trends for Scpharmaceuticals.
Which institutional investors are selling Scpharmaceuticals stock?
Which institutional investors are buying Scpharmaceuticals stock?
SCPH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Citigroup Inc., Schwab Charles Investment Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Scpharmaceuticals.
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $5.89.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $112.18 million. The company earns $-23,810,000.00 in net income (profit) each year or ($8.04) on an earnings per share basis. Scpharmaceuticals employs 29 workers across the globe.
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
